scispace - formally typeset
V

Valeria Lanza

Researcher at National Research Council

Publications -  26
Citations -  399

Valeria Lanza is an academic researcher from National Research Council. The author has contributed to research in topics: Chemistry & Proteasome. The author has an hindex of 10, co-authored 21 publications receiving 302 citations. Previous affiliations of Valeria Lanza include University of Catania.

Papers
More filters
Journal ArticleDOI

New glycoside derivatives of carnosine and analogs resistant to carnosinase hydrolysis: synthesis and characterization of their copper(II) complexes.

TL;DR: It is found that the glycoconjugation protects the dipeptide moiety from carnosinase hydrolysis, thus potentially improving the availability of carnosine and its amide derivative with small sugars such as glucose and lactose.
Journal ArticleDOI

The double faced role of copper in Aβ homeostasis: A survey on the interrelationship between metal dyshomeostasis, UPS functioning and autophagy in neurodegeneration

TL;DR: A chemical perspective of the role of copper in Aβ homeostasis is provided, thus giving the necessary outline to the problem of age-related protein misfolding and altered metallostasis which lead to accumulation processes and consequent decline of neuron functions.
Journal ArticleDOI

New conjugates of superoxide dismutase/catalase mimetics with cyclodestrins

TL;DR: The synthesis of two novel conjugates of salen-type ligands with the beta-cyclodextrin and 6-deoxy-6, which yields compounds with enhanced SOD activity and catalase and peroxidase activities higher than the simple salen complexes.
Journal ArticleDOI

Amino- and chloro-8-hydroxyquinolines and their copper complexes as proteasome inhibitors and antiproliferative agents

TL;DR: The great potential of amino- and chloro- 8-hydroxyquinolines as anticancer agents is suggested and some aspects concerning the activity of 5-amino-8-Hydroxyquinoline, which has been previously proposed as a proteasome inhibitor capable of overcoming resistance to bortezomib are clarified.
Journal ArticleDOI

Repurposing of Copper(II)-chelating Drugs for the Treatment of Neurodegenerative Diseases

TL;DR: It is upheld that drug repurposing makes significant advantages over drug discovery since repositioned drugs had already passed the safety and toxicity tests and sufficient details on their mechanism of action are available to encourage further investigations and clinical trials.